Mammoth Dialysis (FMC) is a medicare approved dialysis facility center in Mammoth, Arizona and it has 12 dialysis stations. It is located in Pinal county at 14786 S Highway 77 - Pob 729, Mammoth, AZ, 85618. You can reach out to the office of Mammoth Dialysis (FMC) at (520) 487-0150. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Mammoth Dialysis (FMC) has the following ownership type - Profit. It was first certified by medicare in April, 2003. The medicare id for this facility is 032598 and it accepts patients under medicare ESRD program.
| Name | Mammoth Dialysis (FMC) |
|---|---|
| Location | 14786 S Highway 77 - Pob 729, Mammoth, Arizona |
| No. of Dialysis Stations | 12 |
| Medicare ID | 032598 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 14786 S Highway 77 - Pob 729, Mammoth, Arizona, 85618 | |
| (520) 487-0150 | |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
| NPI Number | 1104928373 |
| Organization Name | Renal Care Group Mammoth |
| Doing Business As | Renal Care Group Arizona, Llc |
| Address | 14786 S State Hwy 77 Mammoth, Arizona, 85618 |
| Phone Number | (520) 487-0150 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
| Dialysis patients with Hemoglobin data | 12 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 17 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 29 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 260 |
| Percentage of adult patients getting regular hemodialysis at the center | 97 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Mammoth Dialysis (FMC) with elevated calcium levels.
| Patients with hypercalcemia | 33 |
| Hypercalcemia patient months | 297 |
| Patients with Serumphosphor | 35 |
| Patients with Serumphosphor less than 3.5 mg/dL | 10 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 27 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 30 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 8 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 19 |
| Patient months included in arterial venous fistula and catheter summaries | 161 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 81 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 7 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 24 |
| Hospitalization Rate in facility | 223.9 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 494.1 |
| Hospitalization Rate: Lower Confidence Limit | 108 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
The rate of readmission show you whether patients who were being treated regularly at Mammoth Dialysis (FMC) were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 21 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 39.9 |
| Readmission Rate: Lower Confidence Limit | 8.4 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Mammoth Dialysis (FMC) get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | .64 (As Expected) |
| SIR: Upper Confidence Limit | 3.16 |
| SIR: Lower Confidence Limit | .03 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Mammoth Dialysis (FMC)'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 21 |
| Transfusion Rate in facility | 29.2 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 224.1 |
| Transfusion Rate: Lower Confidence Limit | 4.9 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
The rate of mortality show you whether patients who were being treated regularly at Mammoth Dialysis (FMC) lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 125 |
| Mortality Rate in facility | 16.3 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 27.9 |
| Mortality Rate: Lower Confidence Limit | 8.7 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago
Mammoth Dialysis (FMC) Location: 14786 S Highway 77 - Pob 729, Mammoth, Arizona, 85618 Phone: (520) 487-0150 |
News Archive
Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc. today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved NESINA (alogliptin) and the fixed-dose combination (FDC) therapies OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl) for the treatment of type 2 diabetes in adults as adjuncts to diet and exercise.
Using magnetically controlled nanoparticles to force tumour cells to 'self-destruct' sounds like science fiction, but could be a future part of cancer treatment, according to research from Lund University in Sweden.
New advancements in a radiation oncology treatment called IMRT (intensity modulated radiation therapy) are proving far superior to standard radiation procedures used today in safeguarding the healthy tissues surrounding cancerous tumors, and thus improving patient care.
A study in the October 15 issue of the Journal of Clinical Sleep Medicine shows that unrelated to obesity, people with severe SDBs consume a more unhealthy diet, which may be a factor contributing to greater cardiovascular morbidity and mortality. These findings were most evident among women.
While avian influenza has been successfully checked in Western Europe and much of Southeast Asia apart from Indonesia, it is still expanding in Africa and will remain a threat for years to come
› Verified 1 days ago